Skip to Content
Global News Select

FDA Approves TG Therapeutics Inc.'s MS Drug Briumvi

By Josh Beckerman


The U.S. Food and Drug Administration approved TG Therapeutics Inc.'s Briumvi, an antibody indicated for the treatment of relapsing forms of multiple sclerosis.

The drug is also known as ublituximab.

Before TG Therapeutics shares were halted Wednesday afternoon, the stock was up 9% to $8.51.


Write to Josh Beckerman at


(END) Dow Jones Newswires

December 28, 2022 13:57 ET (18:57 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Market Updates

Our Picks